Status:
COMPLETED
Selenium and Prostate Cancer: Clinical Trial on Availability to Prostate Tissue and Effects on Gene Expression
Lead Sponsor:
Wageningen University
Collaborating Sponsors:
World Cancer Research Fund International
Conditions:
Prostatic Neoplasms
Prostate Cancer
Eligibility:
MALE
Phase:
NA
Brief Summary
The aim of this study is to determine whether selenium supplementation leads to changes in selenium levels and gene expression profiles in prostate tissue.
Detailed Description
Rationale: Prostate cancer is a frequently observed malignancy in men, especially in elderly men. Besides diagnosis and treatment, also prevention of prostate cancer is an important point of interest ...
Eligibility Criteria
Inclusion
- male
- biopsy proven prostate cancer
- scheduled for radical prostatectomy
Exclusion
- liver diseases (e.g. hepatitis)
- kidney diseases
- inflammatory bowel diseases
- use of dietary supplements containing selenium
- adjuvant therapy for prostate cancer (e.g. hormonal therapy, HIFU)
- previously or concurrent diagnosed with cancer, other than prostate cancer
Key Trial Info
Start Date :
June 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2011
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00446901
Start Date
June 1 2007
End Date
January 1 2011
Last Update
March 14 2011
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
University Medical Centre St Radboud
Nijmegen, Gelderland, Netherlands, 6500 HB
2
Wageningen University
Wageningen, Gelderland, Netherlands, 6700 EV